Scholar Rock Holding Corp.

As of September 26, 2025, Scholar Rock Holding Corp. shows a neutral trend with mixed signals, being mildly bearish on weekly indicators but bullish on monthly ones, while outperforming the S&P 500 recently but underperforming year-to-date.

As of September 3, 2025, Scholar Rock Holding Corp. has shifted to a mildly bearish trend, indicated by a bearish MACD and moving average, despite a strong annual performance of 292.74% compared to the S&P 500's 17.14%.

As of May 9, 2023, Scholar Rock Holding Corp. is considered overvalued with troubling financial ratios and a significant decline in its valuation grade, indicating severe inefficiencies and worse financial health compared to its peers, despite a strong one-year stock return.

As of June 20, 2025, the technical trend is neutral with mixed signals, showing bullish indicators on the weekly and monthly MACD and Bollinger Bands, but bearish signals from daily moving averages and weekly KST, indicating no strong directional bias.

As of March 2022, the management team of Scholar Rock Holding Corp. includes Mr. David Hallal as Independent Chairman, Mr. Tony Kingsley as President and CEO, and independent directors Ms. Kristina Burow and Dr. Michael Gilman.

Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing monoclonal antibodies for treating neuromuscular disorders, cancer, fibrosis, and anemia. It has a market cap of approximately $2.96 billion and reported a net profit loss of $75 million as of March 2025.

As of Jun 18, Scholar Rock Holding Corp. has a market capitalization of $2.96 billion, with net sales of $0.00 million and a net profit of -$264.16 million over the last four quarters. The balance sheet shows shareholder's funds of $368.63 million and total assets of $474.92 million.